[{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Tocilizumab","moa":"||IL-6-alpha receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Enzene Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"Enzene Biosciences \/ Theramex","highestDevelopmentStatusID":"1","companyTruncated":"Enzene Biosciences \/ Theramex"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Theramex has entered into an agreement with Enzene Biosciences to develop, register and commercialise a biosimilar drug of Roche’s reference medicine RoActemra® (Tocilizumab). Tocilizumab will be available in parenteral vials, subcutaneous prefilled s...

                          Product Name : RoActemra-Generic

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          December 23, 2021

                          Lead Product(s) : Tocilizumab,Methotrexate

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : Theramex

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank